ACOG Strongly Recommends Hormone Therapy for Menopause Symptoms
The American College of Obstetricians and Gynecologists (ACOG) has released new guidelines emphasizing the importance of menopause hormone therapy (MHT) for managing menopause-related symptoms, particularly vasomotor symptoms (VMS) such as hot flashes and sleep disturbances. This comprehensive update, published in the journal *Obstetrics & Gynecology*, provides a robust framework for healthcare providers to treat patients experiencing menopause.
According to ACOG, a significant number of women, ranging from 50% to 92%, report experiencing VMS during menopause. In addition, many face sleep issues, with studies indicating that between 16% and 66% of menopausal individuals experience sleep disturbances. More than a third of women in perimenopause or postmenopause also report depressive symptoms.
Dr. Bruce Pier, a clinical professor and contributor to the guidelines, highlights that misconceptions about the risks associated with hormone therapy have led to hesitancy among both clinicians and patients. The new guidance aims to clarify these misunderstandings and promote individualized treatment options for those affected by menopause.
ACOG strongly endorses the use of MHT, which includes estrogen and progestogens (or estrogen alone for those without a uterus), for individuals experiencing VMS and related sleep disturbances. Additionally, conjugated estrogen plus bazedoxifene is conditionally recommended as an alternative option. Research has shown that these therapies can significantly reduce the frequency and severity of menopause symptoms, as well as improve sleep quality.
For those who cannot or prefer not to use hormone therapy, ACOG recommends several nonhormonal alternatives. Selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) are strongly suggested for symptom management. Currently, paroxetine is the only antidepressant approved by the FDA specifically for VMS. Furthermore, neurokinin receptor antagonists like fezolinetant and elinzanetant have also been approved for managing hot flashes.
In addition to medication, ACOG recommends nonpharmacologic treatments, including cognitive behavioral therapy (CBT), mindfulness practices, regular physical activity, clinical hypnosis, and acupuncture. These approaches are typically suggested to complement medical treatments for a more comprehensive management strategy.
The updated guidelines also aim to address healthcare disparities that exist in menopause care. Research indicates that various factors, including race and socioeconomic status, can impact how women experience menopause and the treatments they receive. ACOG urges clinicians to proactively inquire about menopause symptoms during midlife visits, rather than waiting for patients to bring them up.
The recommendations underscore the importance of shared decision-making between patients and healthcare providers, considering factors such as age, medical history, and personal health risks when determining the best treatment approach. The hope is that this guidance will empower more women to seek the care they need and improve their quality of life during this significant transition.
